
Captopril
Description
Historical Context of Angiotensin-Converting Enzyme (ACE) Inhibitors and Captopril's Discovery
The understanding of the renin-angiotensin-aldosterone system (RAAS) and its role in blood pressure regulation laid the groundwork for the development of ACE inhibitors. Early research in the mid-20th century began to elucidate the components and functions of this complex system. wikipedia.orgahajournals.org However, the precise role of the RAAS in hypertension was initially underestimated. ahajournals.org The discovery of specific inhibitors of this system provided the necessary tools to overcome this prevailing view. ahajournals.org
Discovery from Brazilian Viper Venom Studies
A crucial turning point came from the study of the venom of the Brazilian pit viper, Bothrops jararaca. wikipedia.orgresearchgate.netpharmaceutical-journal.com Studies dating back to 1965 with this venom identified peptides that were found to potentiate the effects of bradykinin, a vasodilator. ahajournals.orgresearchgate.net These bradykinin-potentiating factors (BPFs) were later shown to inhibit the enzyme responsible for the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, which was identified as angiotensin-converting enzyme (ACE) in the mid-1950s. researchgate.netpharmaceutical-journal.com The biochemical and pharmacological properties of these venom peptides, particularly a pentapeptide called BPP5a, were instrumental in the subsequent development of this compound. ahajournals.orgresearchgate.net
Pioneering Role of this compound as the First Orally Active ACE Inhibitor
Following the identification of ACE inhibition as a therapeutic target, the challenge was to develop a compound that was not only a potent ACE inhibitor but also orally bioavailable. Early ACE inhibitory peptides derived from snake venom, such as teprotide, were effective when administered intravenously but lacked oral activity, limiting their clinical utility for chronic conditions like hypertension. researchgate.netlaskerfoundation.orgwikipedia.org this compound, synthesized in 1975 by researchers at E.R. Squibb & Sons (now Bristol-Myers Squibb), represented a major breakthrough as the first orally active ACE inhibitor. wikipedia.orgkarger.com Its approval for medical use in the early 1980s marked a significant advance in cardiovascular medicine. wikipedia.orglaskerfoundation.org
Evolution of Drug Design Concepts leading to this compound
The development of this compound is considered one of the earliest successes of rational drug design, specifically structure-based drug design. wikipedia.orgkarger.comlaskerfoundation.org Researchers, notably David Cushman and Miguel Ondetti at Squibb, built upon the knowledge gained from studying the snake venom peptides and the presumed nature of the ACE active site. wikipedia.orgahajournals.org Recognizing ACE as a zinc-containing metalloprotease similar to carboxypeptidase A, they designed compounds that could interact specifically with the enzyme's active site. wikipedia.orglaskerfoundation.org Based on the structure of the venom peptides and insights from inhibitors of carboxypeptidase A, they synthesized a series of proline derivatives. ahajournals.orgresearchgate.net A key discovery was that replacing a carboxyl group with a sulfhydryl group led to a significant increase in inhibitory potency, resulting in the design of this compound. ahajournals.orglaskerfoundation.org This logical process of constructing molecules for a precise fit with the enzyme's active site was central to this compound's development. ahajournals.org
Overview of this compound's Role in Modulating the Renin-Angiotensin-Aldosterone System (RAAS)
This compound exerts its primary pharmacological effect by inhibiting ACE, a key enzyme in the RAAS. patsnap.comnih.govdrugbank.com The RAAS is a hormonal cascade that plays a critical role in regulating blood pressure, fluid balance, and electrolyte balance. patsnap.comdrugbank.com The system begins with the release of renin from the kidneys, which cleaves angiotensinogen (produced by the liver) to form angiotensin I. patsnap.comdrugbank.com Angiotensin I is a relatively inactive decapeptide. patsnap.comnih.gov ACE, found predominantly in the lungs and kidneys, then converts angiotensin I into the highly active octapeptide angiotensin II. patsnap.comfishersci.senih.gov
Angiotensin II is a potent vasoconstrictor, directly causing the narrowing of blood vessels and increasing blood pressure. patsnap.comgiapreza.com It also stimulates the release of aldosterone from the adrenal glands. patsnap.comdrugbank.com Aldosterone acts on the kidneys to promote the reabsorption of sodium and water, which increases blood volume and further contributes to elevated blood pressure. patsnap.com
By inhibiting ACE, this compound reduces the conversion of angiotensin I to angiotensin II. patsnap.commims.comnih.gov This leads to decreased levels of angiotensin II, resulting in several effects:
Reduced vasoconstriction, promoting vasodilation and lowering blood pressure. patsnap.com
Decreased aldosterone secretion, leading to increased excretion of sodium and water by the kidneys, thus reducing blood volume and blood pressure. patsnap.com
An increase in plasma renin activity, likely due to a loss of the negative feedback inhibition normally exerted by angiotensin II on renin release. drugbank.commims.comnih.gov
Furthermore, ACE is also involved in the degradation of bradykinin, a potent vasodilator. karger.com By inhibiting ACE, this compound can lead to increased levels of bradykinin, which may contribute to its vasodilatory effects. karger.com
Here is a simplified representation of this compound's action within the RAAS:
Component | Normal RAAS Pathway | Effect of this compound |
Renin | Converts Angiotensinogen to Angiotensin I | Increased (due to reduced negative feedback) drugbank.commims.comnih.gov |
Angiotensinogen | Substrate for Renin | Unchanged |
Angiotensin I | Converted to Angiotensin II by ACE | Increased mims.com |
ACE | Converts Angiotensin I to Angiotensin II; degrades Bradykinin | Inhibited patsnap.comnih.govnih.gov |
Angiotensin II | Potent vasoconstrictor; stimulates Aldosterone release | Decreased patsnap.commims.comnih.gov |
Aldosterone | Promotes Na+ and water reabsorption | Decreased patsnap.commims.com |
Bradykinin | Degraded by ACE | Increased (potentially) karger.com |
Scope and Significance of this compound Research in Contemporary Pharmacology
This compound's discovery and characterization have had a profound and lasting impact on contemporary pharmacology. As the first ACE inhibitor, it validated the RAAS as a critical therapeutic target for cardiovascular diseases. wikipedia.orgnih.gov The success of this compound paved the way for the development of numerous other ACE inhibitors with varying pharmacokinetic profiles and structural features, such as enalapril, lisinopril, and ramipril. laskerfoundation.orgwikipedia.orgebi.ac.ukproteopedia.orgnih.gov
Research into this compound and subsequent ACE inhibitors has significantly advanced the understanding of the RAAS and its involvement in not only hypertension and heart failure but also other conditions like diabetic nephropathy and left ventricular dysfunction post-myocardial infarction. laskerfoundation.orgnih.gov The drug design principles employed in the development of this compound, particularly the focus on enzyme active sites and structure-based design, have become fundamental approaches in modern drug discovery for various therapeutic areas beyond the cardiovascular system. wikipedia.orglaskerfoundation.orgnih.gov
Furthermore, studies on this compound continue to provide insights into the nuances of ACE inhibition, including its effects on local tissue RAAS, oxidative stress, and interactions with other vasoactive systems like the kinin-kallikrein system. karger.comnih.gov Although newer ACE inhibitors and other RAAS-modulating drugs like angiotensin II receptor blockers (ARBs) and renin inhibitors (e.g., aliskiren) have been developed, this compound remains a benchmark compound in pharmacological research and clinical practice, underscoring its enduring significance. laskerfoundation.orgebi.ac.ukwikipedia.orgwikipedia.org
Properties
IUPAC Name |
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid | |
---|---|---|
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI |
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI Key |
FAKRSMQSSFJEIM-RQJHMYQMSA-N | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Canonical SMILES |
CC(CS)C(=O)N1CCCC1C(=O)O | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Isomeric SMILES |
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Molecular Formula |
C9H15NO3S | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Related CAS |
1253948-36-5 | |
Record name | L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-, homopolymer | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=1253948-36-5 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
DSSTOX Substance ID |
DTXSID1037197 | |
Record name | Captopril | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID1037197 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Molecular Weight |
217.29 g/mol | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Physical Description |
Solid | |
Record name | Captopril | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0015328 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Solubility |
Freely soluble, Freely soluble in water (approximately 160 mg/mL), Freely soluble in alcohol, chloroform, methylene chloride; sparingly soluble in ethyl acetate, 4.52e+00 g/L | |
Record name | Captopril | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB01197 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Captopril | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/6527 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Captopril | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0015328 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Color/Form |
White to off-white, crystalline powder, Crystals from ethyl acetate/hexane | |
CAS No. |
62571-86-2 | |
Record name | Captopril | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=62571-86-2 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
Record name | Captopril [USAN:USP:INN:BAN:JAN] | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0062571862 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
Record name | Captopril | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB01197 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | captopril | |
Source | DTP/NCI | |
URL | https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=757419 | |
Description | The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. | |
Explanation | Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. | |
Record name | Captopril | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID1037197 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Record name | Captopril | |
Source | European Chemicals Agency (ECHA) | |
URL | https://echa.europa.eu/substance-information/-/substanceinfo/100.057.806 | |
Description | The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness. | |
Explanation | Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page. | |
Record name | CAPTOPRIL | |
Source | FDA Global Substance Registration System (GSRS) | |
URL | https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9G64RSX1XD | |
Description | The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions. | |
Explanation | Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. | |
Record name | Captopril | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/6527 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Captopril | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0015328 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Melting Point |
103-104, 103-104 °C, 106 °C | |
Record name | Captopril | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB01197 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Captopril | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/6527 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Captopril | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0015328 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Analytical and Bioanalytical Methodologies for Captopril Research
Chromatographic Techniques
Chromatographic methods are widely used for the separation and quantification of captopril and its related substances.
High-Performance Liquid Chromatography (HPLC) for Quantitative Analysis in Biological Fluids and Formulations
HPLC is a predominant technique for the analysis of this compound in pharmaceutical and biomedical applications due to its versatility and ability to separate complex mixtures. walshmedicalmedia.com Numerous reversed-phase HPLC methods have been developed and validated for the quantitative determination of this compound in bulk drug, tablets, and biological samples like serum and plasma. researchgate.netresearchgate.netwalshmedicalmedia.com
These methods often utilize C18 columns and mobile phases typically consisting of mixtures of methanol or acetonitrile with water, often adjusted to an acidic pH using acids like phosphoric acid. researchgate.netresearchgate.netresearchgate.net UV detection is commonly employed, with monitoring wavelengths often in the range of 215-227 nm, where this compound exhibits UV absorption. researchgate.netresearchgate.net Some methods have explored different wavelengths like 215, 220, and 225 nm for monitoring. researchgate.net
The sensitivity and selectivity of HPLC methods can be enhanced through various approaches, including pre-column derivatization, which is particularly useful for compounds like this compound that may lack strong chromophores or require stabilization of reactive groups. walshmedicalmedia.comresearchgate.net For instance, a stability-indicating HPLC method for this compound has been developed using pre-column derivatization with Pd(II), enabling detection at 380 nm. researchgate.net
HPLC methods have demonstrated good linearity, accuracy, and precision for this compound analysis. For example, one reversed-phase HPLC method showed linearity in the range of 1.25-50 µg/mL with a correlation coefficient greater than 0.999. researchgate.net The detection limit for this method was reported as 2.0 ng/mL, and the quantification limit was 8.0 ng/mL. researchgate.net Another validated RP-HPLC method for this compound in formulations showed linearity in the range of 0.3–1.5 mg/mL with an r² of 0.9983. researchgate.net
HPLC methods are suitable for routine analysis and are appropriate for therapeutic drug monitoring and pharmacokinetic studies. researchgate.netresearchgate.net
Gas Chromatography (GC)
Gas chromatography has also been utilized for the determination of this compound, although it often requires derivatization due to this compound's polarity and relatively low volatility. tandfonline.comnih.gov GC methods typically involve converting this compound into a more volatile derivative before analysis. tandfonline.comnih.gov
One reported GC method for this compound in tablets involved esterification to improve sensitivity. nih.gov The analysis was performed on a packed column (2% OV-17 on 80-100 mesh Chromosorb W AW-DMCS) operated at 190°C, with both the FID detector and injector port at 220°C. nih.gov Octadecane was used as an internal standard, and the method showed linearity between 0.2 g/L and 1 g/L. nih.gov This method was reported to be sensitive, reproducible, and satisfactory for tablet analysis. nih.gov
Another derivatization-GC method described the determination of this compound using pentafluorobenzyl bromide in acetonitrile with potassium carbonate as a catalyst. tandfonline.comtandfonline.com This derivatization step converted this compound into a derivative with suitable chromatographic properties for separation on an OV-1 column monitored with a flame-ionization detector (FID). tandfonline.com This method had a linear range of 0.25-4.00 µmol and a detection limit of about 40 nmol. tandfonline.comtandfonline.com The method was successfully applied to the analysis of this compound in tablets. tandfonline.com
GC methods, particularly when coupled with mass spectrometry, have also been used for the analysis of this compound and its metabolites in biological tissues. nih.gov
Spectrophotometric Methods (e.g., UV-Vis Spectrophotometry)
Spectrophotometric methods, particularly UV-Vis spectrophotometry, offer relatively simple and cost-effective approaches for this compound analysis, especially in pharmaceutical formulations. ijpsm.comajptr.comlew.ro However, this compound itself does not have a strong chromophore in the easily accessible UV-Vis region, with its UV spectrum showing a band around 200 nm. walshmedicalmedia.commedicopublication.com This often necessitates the use of indirect methods or derivatization to form a colored or UV-absorbing species. ijpsm.comlew.ro
Methods based on UV-Vis spectrophotometry often involve reactions that oxidize the thiol group of this compound or form complexes that exhibit measurable absorbance in the visible range. ijpsm.comlew.ro For example, one approach involves the oxidation of this compound by potassium iodate in sulfuric acid medium, followed by the reaction of liberated iodine with starch to form a blue complex with maximum absorbance at 606 nm. ijpsm.com This method obeyed Beer's law in the concentration range of 2-28 ppm. ijpsm.com
Another spectrophotometric method utilizes the reaction of this compound with a bromate-bromide solution in acid medium, followed by the determination of the unreacted bromine using Fluorescein natrium dye, measuring the absorbance at 436 nm. lew.ro This method showed linearity in the range of 0.2-4.50 µg/mL. lew.ro
Method | Principle | Detection Wavelength (nm) | Linear Range |
UV-Vis Spectrophotometry (KIO₃/Starch) | Oxidation with KIO₃, reaction with starch to form blue complex | 606 | 2-28 ppm |
UV-Vis Spectrophotometry (Br₂/Fluorescein) | Reaction with Br₂, determination of excess Br₂ with Fluorescein natrium | 436 | 0.2-4.50 µg/mL |
UV-Vis Spectrophotometry (Absorbance/AUC) | Direct absorbance or area under the curve measurement after reaction | 400-800 (visible range) | 20-60 µg/mL |
Note: The specific reaction and resulting chromophore determine the optimal detection wavelength.
Capillary Electrophoresis
Capillary electrophoresis (CE), including capillary zone electrophoresis (CZE), has emerged as an alternative technique for the analysis of this compound and its degradation products. ingentaconnect.comresearchgate.netnih.gov CE offers advantages such as short analysis times, high separation efficiency, and low solvent consumption. ingentaconnect.com
CZE methods for this compound often employ UV detection. ingentaconnect.comresearchgate.net The separation is influenced by factors such as electrolyte concentration, pH, applied voltage, and capillary length. ingentaconnect.com For instance, a CZE method for this compound quantitation used a 20 mM phosphate buffer adjusted to pH 7.0 as the running buffer and an applied voltage of 23.90 kV. ingentaconnect.com The method utilized a fused uncoated silica capillary and UV detection. ingentaconnect.com
The stability of this compound solutions is a consideration in CE analysis, and the use of stabilizing agents like sodium metabisulphite has been investigated to prevent degradation. ingentaconnect.com
CE methods have been developed and validated for the quantitative determination of this compound in pharmaceutical formulations. ingentaconnect.comnih.gov A validated CZE method for this compound in tablets, using cetyltrimethylammonium bromide (CTAB) in a sodium phosphate buffer (pH 5.5; 100 mM) with N-acetyl-L-tyrosine as an internal standard, has been reported. nih.gov This method was found to be stability-indicating and applicable for purity control and the determination of degradation products. nih.gov Another CZE method showed linearity over the range of 5-70 µg/mL with an R² of 0.9995, and limits of quantitation and detection of 5 and 1.5 µg/mL, respectively. ingentaconnect.com
Mass Spectrometry (MS) Techniques for this compound and Metabolites
Mass spectrometry (MS), particularly when coupled with chromatographic techniques like GC or HPLC, provides highly sensitive and selective methods for the analysis of this compound and its metabolites in complex matrices, including biological samples. researchgate.netnih.govredalyc.orgresearchgate.netpensoft.netjapsonline.com
GC-MS methods have been developed for the determination of this compound and its metabolites, such as this compound disulfide dimer and S-methyl this compound. nih.govresearchgate.net These methods often involve derivatization steps to make the analytes amenable to GC separation. researchgate.net For instance, one GC-MS method for this compound and its disulfide metabolites used tributylphosphine to reduce the disulfides to this compound before derivatization with N-ethylmaleimide and subsequent esterification. researchgate.net
LC-MS and LC-tandem mass spectrometry (LC-MS/MS) are powerful techniques for the analysis of this compound in biological fluids like plasma. researchgate.netredalyc.orgpensoft.netjapsonline.com LC-MS/MS methods offer high sensitivity, specificity, and throughput, making them suitable for pharmacokinetic studies and bioequivalence trials. researchgate.netredalyc.orgpensoft.netjapsonline.com These methods typically involve sample preparation steps like protein precipitation or solid-phase extraction (SPE) to isolate the analyte from the biological matrix. researchgate.netjapsonline.com
LC-MS/MS methods often employ reversed-phase columns and gradient elution with mobile phases containing organic solvents (e.g., acetonitrile) and aqueous buffers or acidic modifiers (e.g., formic acid). pensoft.netjapsonline.com Detection is performed using a mass spectrometer in positive or negative ionization mode, often in multiple reaction monitoring (MRM) mode for enhanced selectivity and sensitivity. researchgate.netjapsonline.com
Reported LC-MS/MS methods for this compound in human plasma have demonstrated high sensitivity with low limits of quantification. researchgate.netjapsonline.com For example, one method had a lower limit of quantification of 10 ng/mL, with a linear dynamic range of 10-2000 ng/mL. japsonline.com Another GC-MS method for this compound in human plasma reported a limit of quantification of 0.5 ng/mL. researchgate.net LC-MS/MS is also valuable for investigating the metabolism of this compound and simultaneously measuring multiple compounds, including metabolites. pensoft.net
Derivatization Strategies for this compound Analysis
Derivatization plays a crucial role in the analysis of this compound, particularly for techniques like GC and some spectrophotometric and HPLC methods. tandfonline.comwalshmedicalmedia.comresearchgate.netnih.gov The primary reasons for derivatization are to improve the chromatographic properties (e.g., volatility for GC), enhance detection sensitivity (e.g., by introducing a chromophore or fluorophore), and stabilize the reactive thiol group. walshmedicalmedia.commdpi.com
For GC analysis, derivatization is necessary to convert the polar and relatively non-volatile this compound into a more volatile form. tandfonline.comnih.gov Esterification is one approach used for this purpose. nih.gov Another strategy involves the reaction of the thiol group with reagents like pentafluorobenzyl bromide. tandfonline.comtandfonline.com
In HPLC and spectrophotometric methods, derivatization can be used to create a species that is more easily detectable by UV-Vis or fluorescence detectors. walshmedicalmedia.commdpi.com For instance, complexation with metal ions like Pd(II) has been used as a pre-column derivatization strategy for HPLC with photometric detection. researchgate.net Reactions that produce colored compounds are employed in spectrophotometric methods. ijpsm.comlew.ro
Derivatization can be performed offline (pre-column or pre-capillary) or online (post-column or in-column/in-capillary). walshmedicalmedia.commdpi.comencyclopedia.pub Online derivatization approaches offer advantages such as reduced sample and reagent consumption and potential for automation. mdpi.comencyclopedia.pub
The selection of a derivatization strategy depends on the analytical technique used, the matrix of the sample, and the specific analytical goal (e.g., quantitative analysis of the parent drug or simultaneous determination of metabolites). walshmedicalmedia.com Given the susceptibility of the thiol group to oxidation, derivatization is often employed to stabilize this compound during sample preparation and analysis. walshmedicalmedia.com
Validation of Analytical Methods in Research
The accurate and reliable quantification of this compound is crucial in various research settings, including pharmaceutical analysis, pharmacokinetic studies, and stability assessments. Validated analytical methods ensure that the data obtained is dependable and suitable for its intended purpose. Validation typically involves assessing parameters such as linearity, accuracy, precision, specificity, detection limit, quantitation limit, and robustness, often following guidelines from regulatory bodies like the International Conference on Harmonisation (ICH).
Numerous analytical techniques have been developed and validated for this compound analysis, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), spectrophotometry, spectrofluorimetry, capillary electrophoresis, and electroanalytical methods acs.org. Reversed-phase HPLC (RP-HPLC) is a frequently employed method in pharmaceutical research due to its versatility and ability to separate this compound from related substances and degradation products scielo.brijpsonline.com. Spectrophotometric methods, often involving derivatization due to this compound's limited UV absorption at higher wavelengths, are also utilized ijpsm.comresearchgate.netajpaonline.com.
Validation studies for this compound analytical methods often focus on different matrices, such as pharmaceutical formulations (tablets) and biological samples (e.g., plasma, tissue homogenates).
Key Validation Parameters and Research Findings
Linearity: This parameter assesses the method's ability to yield results directly proportional to the analyte concentration within a defined range. Research has shown excellent linearity for various methods. For instance, a UV-Vis spectrophotometric method for this compound in tablets demonstrated linearity in the concentration range of 20-60 µg/mL with correlation coefficients of 0.9998 and 0.9994 for absorbance and area under the curve methods, respectively. ijpsm.com. Another spectrophotometric method showed linearity between 2-28 ppm ijpsm.com. An RP-HPLC method for this compound in rabbit plasma exhibited excellent linearity (R² = 0.999) over a range of 3.125–100 µg/mL akjournals.com. For this compound in mucoadhesive tablets, RP-HPLC methods showed linearity with R² values of 0.9993 for assay (5–75 ppm) and 0.9992 for dissolution (5.6–41.7 ppm) japsonline.com.
Accuracy: Accuracy measures the closeness of test results obtained by the method to the true value. It is often expressed as percentage recovery. Validation studies for this compound analysis have reported high recovery rates. A UV-Vis spectrophotometric method showed average percentage recoveries between 95.33% and 101.55% for this compound in patent and generic tablets ijpsm.com. An RP-HPLC method for this compound in rabbit plasma showed mean percentage recoveries ranging from 97% to 100.6% akjournals.com. For this compound in mucoadhesive tablets, RP-HPLC methods demonstrated average recoveries of 100% for the assay method and 99% for the dissolution method japsonline.com. Recovery studies from spiked biological samples like liver, lung, and kidney tissue homogenates and plasma using an HPLC method with derivatization showed relative recoveries in the range of 93.3% to 105.3% psu.edu.
Precision: Precision refers to the agreement among individual test results when the method is applied repeatedly to multiple samplings of a homogeneous sample. It is usually expressed as relative standard deviation (RSD). Low RSD values indicate good precision. Studies have reported good precision for this compound analysis methods. An RP-HPLC method for this compound in rabbit plasma showed intra- and inter-day precision (% RSD) less than 2% akjournals.com. For this compound in mucoadhesive tablets, the RSD values for precision were 1.5% for the assay method and 1.7% for the dissolution method japsonline.com. Repeatability and intermediate precision for an HPLC method for this compound extemporaneous preparations showed %RSD less than 2% researchgate.net.
Specificity: Specificity is the ability of the method to measure the analyte accurately in the presence of other components that may be expected to be present, such as impurities, degradation products, and excipients. Various methods have demonstrated specificity for this compound. RP-HPLC methods are often developed to be stability-indicating, separating this compound from its degradation products, particularly the disulfide dimer scielo.brijpsonline.com. Validation of an RP-HPLC method for related substances in a this compound certified reference material candidate showed sufficient resolution between this compound and this compound disulfide peaks scielo.br. Spectrophotometric methods involving derivatization are designed to react specifically with the thiol group of this compound ijpsm.comresearchgate.net.
Detection Limit (LOD) and Quantitation Limit (LOQ): LOD is the lowest analyte concentration that can be reliably detected, while LOQ is the lowest concentration that can be quantitatively determined with acceptable accuracy and precision. These limits are important for methods used in trace analysis or for detecting impurities. Reported LOD and LOQ values vary depending on the method and matrix. A spectrophotometric method reported LOD and LOQ of 0.08 and 0.26 mg/mL, respectively ijpsm.com. An RP-HPLC method for this compound in rabbit plasma had LOD and LOQ of 3.10 and 9.13 ng/mL, respectively akjournals.com. For an automated zone fluidics-based sensor for dissolution studies, LOD and LOQ were 0.6 µg/mL and 2.78 µg/mL (corresponding to 1% and 5% of maximum expected concentration), respectively mdpi.com. An HPLC method with derivatization reported a detection limit of 200 fmol/20 µL injection volume and an LLOQ of 10 nM in biological samples psu.edu.
Robustness: Robustness evaluates the capacity of the method to remain unaffected by small, deliberate variations in method parameters. Studies assess the impact of minor changes in factors like mobile phase composition, flow rate, pH, and temperature on method performance. An RP-HPLC method validation included robustness testing by evaluating the impact of small variations in wavelength, flow rate, and phosphoric acid concentration, with resulting RSD values less than 2% indicating robustness scielo.brdergipark.org.tr. An automated zone fluidics-based sensor showed satisfactory robustness with variations in flow rate, reagent concentrations, injection volume, and wavelength causing relative errors less than ±5% mdpi.com.
Data Tables
Here are some examples of data extracted from research findings on the validation of analytical methods for this compound:
Table 1: Linearity and Correlation Coefficient of Selected Methods
Method Type | Matrix | Concentration Range | Correlation Coefficient (R²) | Reference |
UV-Vis Spectrophotometry | Tablets | 20 - 60 µg/mL | 0.9998 (Absorbance), 0.9994 (Area under curve) | ijpsm.com |
UV-Vis Spectrophotometry | Tablets, Water Samples | 2 - 28 ppm | Not specified, Beer's law obeyed | ijpsm.com |
RP-HPLC | Rabbit Plasma | 3.125 – 100 µg/mL | 0.999 | akjournals.com |
RP-HPLC (Assay) | Mucoadhesive Tablet | 5 – 75 ppm | 0.9993 | japsonline.com |
RP-HPLC (Dissolution) | Mucoadhesive Tablet | 5.6 – 41.7 ppm | 0.9992 | japsonline.com |
HPLC with Derivatization | Biological Samples | 10 – 2500 nM | 0.999 | psu.edu |
HPLC | Extemporaneous Preps | 0.75 - 20 μg/mL | 0.9995 | researchgate.net |
RP-HPLC | Bulk, Dosage Form | 0.5 - 200 µg/mL (with IS) | > 0.999 | dergipark.org.tr |
Table 2: Accuracy (Percentage Recovery) of Selected Methods
Method Type | Matrix | Sample Type/Levels | Average Recovery (%) | Reference |
UV-Vis Spectrophotometry | Tablets | Patent, Generic | 95.33 - 104.55 | ijpsm.com |
RP-HPLC | Rabbit Plasma | Not specified | 97 - 100.6 | akjournals.com |
RP-HPLC (Assay) | Mucoadhesive Tablet | 35, 50, 65 ppm | 100 | japsonline.com |
RP-HPLC (Dissolution) | Mucoadhesive Tablet | 5.6, 22.2, 27.8, 36.1 ppm | 99 | japsonline.com |
HPLC with Derivatization | Biological Samples | Liver, Lung, Kidney, Plasma | 93.3 - 105.3 | psu.edu |
HPLC | Extemporaneous Preps | Not specified | 97.4 - 99.8 | researchgate.net |
RP-HPLC | Commercial Dosage Form | Not specified | 99.45 - 102.55 | dergipark.org.tr |
Table 3: Precision (% RSD) of Selected Methods
Method Type | Matrix | Precision Type | % RSD | Reference |
RP-HPLC | Rabbit Plasma | Intra-day, Inter-day | < 2 | akjournals.com |
RP-HPLC (Assay) | Mucoadhesive Tablet | Precision | 1.5 | japsonline.com |
RP-HPLC (Dissolution) | Mucoadhesive Tablet | Precision | 1.7 | japsonline.com |
RP-HPLC (Assay) | Mucoadhesive Tablet | Ruggedness (2 analysts, 3 days) | 1.6 | japsonline.com |
RP-HPLC (Dissolution) | Mucoadhesive Tablet | Ruggedness (2 analysts, 3 days) | 2.7 | japsonline.com |
HPLC with Derivatization | Biological Samples | Within-run, Between-run | 0.5, 3.8 | psu.edu |
HPLC | Extemporaneous Preps | Repeatability, Intermediate Precision | < 2 | researchgate.net |
RP-HPLC | Bulk Form | Robustness | < 2 | dergipark.org.tr |
Table 4: Detection Limit (LOD) and Quantitation Limit (LOQ) of Selected Methods
Method Type | Matrix | LOD | LOQ | Reference |
UV-Vis Spectrophotometry | Not specified | 0.08 mg/mL | 0.26 mg/mL | ijpsm.com |
RP-HPLC | Rabbit Plasma | 3.10 ng/mL | 9.13 ng/mL | akjournals.com |
Automated Zone Fluidics (Dissolution) | Dissolution Medium | 0.6 µg/mL (1%) | 2.78 µg/mL (5%) | mdpi.com |
HPLC with Derivatization | Biological Samples | 200 fmol/20 µL inj. | 10 nM | psu.edu |
RP-HPLC | Bulk, Dosage Form | Not specified | Not specified | dergipark.org.tr |
Spectrophotometry | Not specified | 1.26-2.38 µg/mL | Not specified | acs.org |
These validation studies highlight the suitability of various analytical methods for the reliable determination of this compound in different research matrices, providing confidence in the quantitative data generated.
Drug Development and Formulation Research
Challenges in Captopril Formulation (e.g., Water Solubility, Stability)
This compound's inherent properties pose considerable hurdles in developing stable and controlled-release formulations. A primary challenge is its high water solubility. itmedicalteam.plresearchgate.net While high solubility can be advantageous for immediate release, it makes it difficult to control the dissolution rate for sustained delivery, often leading to dose dumping or a burst effect in sustained-release formulations. itmedicalteam.pl
Another critical challenge is the chemical instability of this compound, particularly its susceptibility to degradation. This compound is unstable in alkaline intestinal pH and undergoes a pseudo-first-order degradation reaction as the pH increases. itmedicalteam.plresearchgate.net The primary degradation pathway involves oxidation, leading to the formation of this compound disulfide (dimer). itmedicalteam.plscielo.brchuv.chscielo.brresearchgate.net This oxidative degradation is a significant concern, especially in aqueous solutions, compromising the drug's therapeutic effect. itmedicalteam.plscielo.br Furthermore, the presence of food has been shown to decrease the bioavailability of oral this compound. itmedicalteam.plmims.comijpsjournal.com The drug also exhibits a mixed absorption profile in the gastrointestinal tract, involving both passive and peptide-carrier mediated transport. itmedicalteam.pl
Approaches for Oral Sustained/Controlled Release Formulations
While the focus is often on sustained release, sublingual formulations have been developed for this compound to achieve a rapid onset of action, particularly in situations requiring a swift reduction in blood pressure, such as hypertensive emergencies. itmedicalteam.plekb.egtishreen.edu.synih.gov Sublingual administration allows for direct absorption into the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism, leading to a more rapid attainment of peak plasma concentrations compared to oral administration. itmedicalteam.plijpsjournal.comekb.eg Studies suggest that sublingual absorption can be significantly higher than the oral route for some drugs. ekb.eg
Research in this area has focused on formulating sublingual tablets with rapid disintegration properties. The use of superdisintegrants like crosscarmellose sodium, crosspovidone, and sodium starch glycolate is crucial for achieving fast disintegration times, typically under 30 seconds. ekb.egtishreen.edu.sy For instance, one study reported an optimized sublingual formulation with a disintegration time of 13.04 seconds and over 85% drug release within 5 minutes. ekb.egbrieflands.com The addition of agents like citric acid has also been explored to lower the pH in the buccal cavity, potentially enhancing this compound absorption. ekb.eg
Microparticulate systems have been investigated as a means to achieve sustained release and potentially targeted delivery of this compound. itmedicalteam.pl
Studies have explored the use of Bovine Serum Albumin (BSA) as a carrier for this compound microparticles. Microparticles prepared using an emulsification-heat stabilization technique demonstrated controlled release of this compound for up to 24 hours in in vitro studies. itmedicalteam.plnih.govresearchgate.net In vivo studies in hypertensive rats showed that these BSA microparticles resulted in preferential drug targeting to organs such as the liver, lungs, kidneys, and spleen. itmedicalteam.plnih.govresearchgate.net
Cellulose Propionate (CP) has also been utilized in the preparation of this compound microparticles via the solvent evaporation technique. These microparticles exhibited sustained release characteristics, with the release kinetics primarily following a diffusion mechanism. itmedicalteam.plresearchgate.netnih.gov Oral administration of selected CP microparticle formulations to hypertensive rats led to a gradual decrease in systolic blood pressure over a 24-hour period, demonstrating their potential as a sustained-release delivery system. itmedicalteam.plresearchgate.netnih.gov Factors such as polymer molecular weight, composition, and drug-to-polymer ratios influence the encapsulation efficiency and release profiles of these microparticles. researchgate.netnih.gov An initial burst release is sometimes observed, which has been attributed to the dissolution of this compound crystals present on the surface or embedded in the superficial layer of the microparticle matrix. researchgate.netnih.gov
Sublingual Tablets for Rapid Action
Enhancing Bioavailability Research
This compound's oral bioavailability is approximately 60-75%, and this is reduced when the drug is taken with food. mims.comijpsjournal.com Research into this compound formulations often aims to enhance bioavailability by addressing issues such as degradation, poor absorption in certain parts of the GI tract, and food interactions. itmedicalteam.plresearchgate.net
Beyond sustained-release approaches, other strategies have been explored to improve this compound's bioavailability. Sublingual administration, as mentioned earlier, enhances bioavailability by bypassing the first-pass metabolism. ijpsjournal.comekb.eg Oral dispersible films (ODFs) loaded with this compound have shown promise in enhancing bioavailability. One study reported a significant increase in bioavailability, with the area under the curve (AUC) being 1.43 times higher for the optimized ODF compared to conventional tablets. nih.gov These ODFs also prolonged the time to reach peak plasma concentration (Tmax). nih.gov Semisolid oily matrix systems incorporating ascorbic acid have also been investigated with the goal of improving this compound bioavailability under non-fasting conditions. itmedicalteam.pl The development of microparticulate systems using carriers like BSA is also partly aimed at enhancing bioavailability by localizing the drug at the absorption site. itmedicalteam.pl
Drug Stability Studies
The stability of this compound is a critical factor in its formulation and shelf life. This compound is known to be susceptible to degradation, primarily through oxidation to its disulfide dimer, particularly in the presence of moisture and at higher pH values. itmedicalteam.plscielo.brchuv.chscielo.brresearchgate.net This degradation follows pseudo-first-order kinetics, with pH being a significant influencing factor; the drug is less stable at alkaline pH. itmedicalteam.plresearchgate.netscielo.br
Extensive stability studies have been conducted on this compound in various formulations and storage conditions. Research has evaluated the stability of this compound in different aqueous vehicles, including distilled water, tap water, mineral water, and syrups. scielo.brchuv.chresearchgate.netresearchgate.netnih.govnih.govscielo.br The impact of various additives, such as chelating agents (e.g., EDTA) and antioxidants (e.g., ascorbic acid, sodium metabisulphite), on stability has also been studied. scielo.brchuv.chresearchgate.netresearchgate.netnih.gov
Findings from these studies highlight the importance of formulation composition and storage conditions for maintaining this compound stability. For liquid formulations, the use of EDTA and buffering agents to maintain a low pH (around 3.85) has been shown to improve stability. scielo.brchuv.chnih.gov Storage temperature is a crucial factor, with lower temperatures (e.g., 4°C or 2-8°C) significantly enhancing stability compared to room temperature or higher temperatures. scielo.brchuv.chresearchgate.netnih.govresearchgate.netresearchgate.netnih.govnih.gov Studies have indicated that this compound is more stable in distilled or purified water compared to tap water or mineral water. researchgate.netnih.gov
Coating techniques have also been explored to improve the stability of solid this compound formulations. Coating granules with polymers such as ethylcellulose has been shown to increase this compound stability. researchgate.net Stability studies typically involve monitoring the concentration of intact this compound and its degradation product, this compound disulfide, often using high-performance liquid chromatography (HPLC). scielo.brresearchgate.netresearchgate.netnih.govnih.gov While preservative-free oral solutions are sometimes preferred, their shelf life can be limited, especially when stored under refrigeration, unless supported by comprehensive stability data. scielo.br Research has demonstrated that extemporaneously prepared oral liquid formulations containing stabilizers like disodium edetate at a low pH can maintain chemical stability for extended periods, such as 12 months when stored in glass bottles at room temperature. nih.gov
Here is a summary of some research findings on this compound stability:
Formulation Type | Vehicle/Additives | Storage Conditions | Observed Stability / Key Findings | Source |
Oral Liquid Suspension | Citric acid, Vitamin C (4, 5 mg/mL) | 2-8°C (90 days), 30°C (60 days) | Vitamin C increased redispersibility; Citric acid lowered pH (2.50-2.80); Higher temp decreased stability; Stabilizers helped maintain >90% this compound for 90 days at 2-8°C. | researchgate.net |
Oral Liquid Solution (1 mg/mL) | Purified water, 0.1% Disodium edetate (EDTA-Na) | 5°C, Room Temperature | Chemically and microbiologically stable for two years. | chuv.ch |
Oral Liquid Solutions (1, 5 mg/mL) | Sterile water, Sorbitol, Disodium edetate (0.1 mg/mL), Sodium benzoate | 22°C (12 months) | Maintained >90% initial concentration for 12 months; Stabilized with EDTA at low pH. | nih.gov |
Aqueous Formulation (1 mg/mL) | Distilled chemically pure water | 4°C | Stable for 30 days. Less stable with EDTA, syrup, ascorbic acid, sodium ascorbate, sodium metabisulphite. | researchgate.netnih.gov |
Aqueous Formulation (1 mg/mL) | Distilled water | 4°C | Stable for 30 days in PVC container protected from light. | scielo.br |
BSA Microparticles | - | 4°C | Maximum drug content and closest in vitro release to initial data. | nih.govresearchgate.net |
Coated Granules | Ethylcellulose, Methylcellulose, Polyvinylpyrrolidone | Various (3 months) | Coating, especially with ethylcellulose, increased stability. | researchgate.net |
Future Research Directions and Emerging Concepts
Investigation of Captopril's "Pleiotropic" Effects beyond RAAS Inhibition
Beyond its canonical inhibition of ACE and subsequent reduction in angiotensin II levels, research is delving into the "pleiotropic" effects of this compound – effects that are independent of the RAAS pathway. Studies suggest that this compound may influence various biological processes, including inflammation and immune responses. For instance, this compound has been shown to modulate chemotaxis, motility, adhesion, differentiation, activation, and cytokine and chemokine production of immune cells. aai.org Investigations in experimental autoimmune myocarditis models have demonstrated that this compound can significantly reduce the incidence and severity of the condition, accompanied by a reduction in heart weight to body weight ratio and heart weight. aai.org This amelioration was linked to interference with cell-mediated immunity, as evidenced by reduced delayed-type hypersensitivity responses. aai.org Further research is needed to fully elucidate the mechanisms behind these non-RAAS-mediated effects and their potential therapeutic implications in various disease states.
Comparative Studies with Newer Angiotensin System Modulators (e.g., ARBs)
Comparative studies between this compound and newer angiotensin system modulators, such as Angiotensin II Receptor Blockers (ARBs), remain an important area of investigation. These studies aim to assess the relative efficacy and outcomes of these different drug classes in various patient populations and conditions. Early trials like the ELITE (Evaluation of Losartan in the Elderly) study compared losartan (an ARB) with this compound in elderly patients with heart failure, initially suggesting a potential reduction in sudden death with losartan, although a larger subsequent trial (ELITE II) did not find a significant mortality benefit for losartan over this compound. nih.govccjm.orgoup.comnih.gov The VALIANT (Valsartan in Acute Myocardial Infarction) trial also compared valsartan, this compound, and their combination in patients after myocardial infarction complicated by left ventricular dysfunction, heart failure, or both. nih.govajmc.com While ARBs are often considered in patients intolerant to ACE inhibitors due to side effects like cough, ongoing research continues to refine our understanding of the optimal use of these drug classes, either alone or in combination. ccjm.org
Genetic and Genomic Influences on this compound Response (e.g., ACE Genotype)
The influence of genetic and genomic factors on individual responses to this compound is an active area of research. Polymorphisms in the ACE gene, particularly the insertion/deletion (I/D) polymorphism, have been investigated for their potential association with variations in ACE activity and, consequently, the effectiveness of ACE inhibitors like this compound. tandfonline.comnih.govtandfonline.comoup.com While some studies have explored the correlation between ACE I/D genotypes and blood pressure reduction with this compound therapy, findings have been conflicting. tandfonline.comtandfonline.compharmgkb.orgresearchgate.netnih.gov For example, a study in Indonesian hypertensive patients found no statistically significant association between ACE I/D genotypes and blood pressure reduction following this compound treatment. tandfonline.comtandfonline.comnih.gov Conversely, other research has suggested that certain ACE genotypes might be associated with increased or decreased response to this compound in specific patient populations, such as those with diabetes mellitus. pharmgkb.org Further research is needed to identify other genetic and genomic markers that may predict individual responses to this compound and pave the way for personalized medicine approaches. Polymorphisms in the ACE2 gene have also been investigated for their association with hypertension and antihypertensive effects of this compound, particularly in women. researchgate.net
Novel Therapeutic Combinations Involving this compound
Exploring novel therapeutic combinations involving this compound is another avenue of future research. Combining this compound with other classes of drugs may offer synergistic benefits or address limitations of monotherapy. Studies have investigated the combination of this compound with calcium channel blockers, demonstrating an additive effect on blood pressure reduction in patients with essential hypertension, although the effect was noted to be relatively short-acting. ahajournals.orgahajournals.orgnih.gov The combination of this compound with hydrochlorothiazide (HCTZ) has also been explored in sustained-release formulations to potentially improve antihypertensive efficacy. semanticscholar.org Furthermore, research has investigated the combination of this compound with pentoxifylline in reducing proteinuria in diabetic nephropathy, suggesting an additive effect compared to this compound alone. tandfonline.com These studies highlight the potential for developing new combination therapies to optimize patient outcomes.
Elucidation of this compound's Effects in Specific Disease Models (e.g., Infantile Hemangioma, Liver Diseases)
Research continues to explore the effects of this compound in specific disease models beyond its traditional cardiovascular indications. The role of the RAAS in the biology of infantile hemangiomas (IH) has led to investigations into the effect of this compound in this condition. frontiersin.orgamegroups.cnamegroups.orgnih.govjscimedcentral.com Studies have suggested that this compound may induce accelerated involution of IH, supporting the involvement of the RAAS in this proliferative disorder. frontiersin.orgamegroups.cnamegroups.orgjscimedcentral.com However, comparative studies with other treatments, such as propranolol, have shown propranolol to be more effective. amegroups.cnamegroups.org
In the context of liver diseases, studies are investigating the potential protective effects of this compound. Research in animal models of inflammation-induced liver injury has suggested that this compound may improve liver function and attenuate inflammation and oxidative stress. tandfonline.com Additionally, studies have explored the protective effects of this compound against hepatotoxicity induced by certain medications, such as cyclophosphamide, in animal models. ekb.egekb.eg While some research in patients with liver cirrhosis has indicated that this compound inhibits the RAAS, it did not significantly decrease portal venous pressure, suggesting it may not favorably influence the incidence of bleeding in these patients. nih.gov Further research is needed to fully understand the role of this compound in various liver pathologies. Physiologically based pharmacokinetic (PBPK) models are also being developed to predict this compound pharmacokinetics in chronic diseases like chronic kidney disease (CKD) and chronic heart failure (CHF), which could aid in tailoring dosages for these populations. researchgate.netresearchgate.net
Q & A
Q. What structural and mechanistic principles guided the rational design of captopril as an ACE inhibitor?
this compound was developed using a receptor-based design approach targeting the zinc-binding active site of angiotensin-converting enzyme (ACE). Its sulfhydryl group mimics the carboxyl group of the ACE substrate, enabling competitive inhibition. This design was informed by studies on the venom peptide teprotide, which revealed ACE's catalytic mechanism . Methodologically, crystallographic data and structure-activity relationship (SAR) studies were critical for optimizing binding affinity and selectivity .
Q. How can Quality by Design (QbD) principles be applied to optimize this compound formulations for controlled release?
QbD methodologies involve systematic experimentation with variables like polymer composition (e.g., HPMC K15M and ethylcellulose) to achieve target dissolution profiles. For example, a central composite design (CCD) can model the impact of excipient ratios on drug release kinetics, ensuring robustness in sustained-release formulations. Dissolution testing remains the critical quality attribute (CQA) for validation .
Q. What validated analytical methods are recommended for quantifying this compound in biological matrices?
Reverse-phase high-performance liquid chromatography (RP-HPLC) with UV detection is widely used, offering retention times of ~3.1 minutes under optimized conditions (acetonitrile: 28–36% v/v, pH 2.8–3.6) . For higher sensitivity, LC-HRMS with a mass window of 1 ppm provides selective quantification in dried blood spots, minimizing matrix interference (e.g., m/z 218.0845 for this compound) .
Advanced Research Questions
Q. How do experimental variables (e.g., age, sex, dosage) influence the reproducibility of this compound's therapeutic outcomes in preclinical models?
Studies in renal injury models highlight confounding factors like mixed-sex cohorts and age ranges (3–12 months in rats), which increase data variability. To mitigate this, stratified randomization and covariance analysis (adjusting for age/sex) are recommended. For example, this compound’s efficacy in reducing HW/BW ratios in cardiomyopathic rats was significant only after controlling for these variables .
Q. What mechanisms explain this compound's antiangiogenic effects, and how can these be reconciled with its primary ACE inhibition role?
this compound inhibits endothelial cell migration and metalloproteinases (72-/92-kDa) via zinc chelation, independent of ACE. This biphasic dose-response (effective at <10 µM and millimolar ranges) suggests dual pathways: ACE-dependent vasodilation and ACE-independent antiangiogenesis. In vitro scratch assays and corneal neovascularization models are key for mechanistic validation .
Q. Why do contradictory results arise in studies investigating this compound's metabolic effects (e.g., insulin sensitivity, lipid profiles)?
In SHRSP-ZF rats, this compound failed to improve glucose, insulin, or triglyceride levels despite its antihypertensive action. This discrepancy may stem from tissue-specific ACE expression or compensatory pathways (e.g., RAAS upregulation). Dual inhibition strategies (e.g., combining this compound with PPAR-γ agonists) and tracer-based metabolic flux analysis are proposed to clarify these interactions .
Q. How can novel delivery systems (e.g., transdermal films, biosensors) enhance this compound's therapeutic applicability?
Niosomal-loaded transdermal films improve bioavailability by encapsulating this compound in non-ionic surfactants, achieving sustained release (>12 hours) with minimal dose requirements. For real-time monitoring, smartphone-integrated biosensors using N-CQDs-MnO₂ nanotubes enable dual-mode detection of this compound in plasma (LOD: 0.1 µM) .
Data Contradiction Analysis
Q. How should researchers interpret conflicting data on this compound's lifespan-extending effects in murine models?
The ITP study reported increased median lifespan in mice, but male results were inconclusive due to experimental artifacts. Replication with higher doses (planned by ITP) and strain-specific genetic profiling (e.g., C57BL/6 vs. BALB/c) are advised. Notably, mice lack hypertension-related mortality, necessitating alternative models (e.g., senescence-accelerated mice) .
Q. What methodological refinements address variability in this compound's pharmacokinetic (PK) studies?
Interspecies differences in absorption (e.g., low Caco-2 permeability vs. in vivo bioavailability) require physiologically based pharmacokinetic (PBPK) modeling. Parameterization with plasma protein binding (103.2% recovery in LC-MS) and enterohepatic recirculation data improves predictive accuracy .
Tables for Key Findings
Retrosynthesis Analysis
AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.
One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.
Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.
Strategy Settings
Precursor scoring | Relevance Heuristic |
---|---|
Min. plausibility | 0.01 |
Model | Template_relevance |
Template Set | Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis |
Top-N result to add to graph | 6 |
Feasible Synthetic Routes
Featured Recommendations
Most viewed | ||
---|---|---|
Most popular with customers |
Disclaimer and Information on In-Vitro Research Products
Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.